Uveitis Clinical Trial Pipeline Expands as 15+ Companies Advance 15+ Targeted Ocular Inflammation Therapies Toward Market Entry, Finds DelveInsight | Santen, Clearside Biomedical, Tarsier Pharma

DelveInsight's "Uveitis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others, developing 15+ pipeline drugs in the Uveitis pipeline landscape.
DelveInsight's "Uveitis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing 15+ pipeline drugs in the Uveitis pipeline landscape. It covers Uveitis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, development stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Uveitis treatment landscape. Learn more about the evolving pipeline Uveitis @ https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Uveitis Pipeline Report

*
In January 2026, Novaliq received FDA IND clearance for NOV05 (tacrolimus eye drops) to advance into Phase 2 EYETAC trial for non-infectious anterior uveitis (NIAU), starting Q1 2026.

*
In October 2025, FDA approved expanded pediatric indications for Celltrion's YUFLYMA (adalimumab-aaty), including uveitis in patients aged 2 years and older.

*
In September 2025, Priovant Therapeutics received FDA Fast Track Designation for brepocitinib in non-anterior non-infectious uveitis (NIU); CLARITY Phase 3 trial enrollment ongoing

*
In March 2025, FDA approved expanded label for ANI Pharmaceuticals' ILUVIEN (fluocinolone acetonide intravitreal implant) to treat chronic non-infectious uveitis affecting the posterior segment (NIU-PS).

*
The leading Uveitis companies include Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others, reflecting a mix of large pharma and ophthalmologyfocused biotechs.

*
Promising Uveitis therapies highlighted by DelveInsight span a broad mechanistic spectrum and include XIPERE, YUTIQ, ILUVIEN, TRS01, OCS02 (licaminlimab), RG6179, Baricitinib, Izokibep, EYS606, Brepocitinib, OCS01, Sirolimus (DE109), CER001, OK101, and others that target ocular inflammation via corticosteroid, JAK, cytokine, and TNF pathways or novel delivery technologies.

Download the Uveitis pipeline report for the updates and recent advancements in Uveitis care @ Uveitis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Uveitis Emerging Drugs Profile

*
TRS01: Tarsier Pharma

TRS01 is a steroidfree ophthalmic solution (eyedrop formulation of dazdotuftide) in development for active noninfectious anterior uveitis, including patients with uveitic glaucoma. In the Phase 3 TRS4Vision trial, TRS01 1% eye drops demonstrated clinically meaningful antiinflammatory activity, with resolution of inflammation and reduction in ocular pain comparable to steroid eye drops while maintaining a favorable intraocular pressure (IOP) profile, supporting its potential as a safer firstline alternative in uveitic glaucoma. Supported by Phase 3 data and a successful Type C meeting, Tarsier and the FDA have agreed on a registrational program focused on endpoints that capture TRS01's risk-benefit profile, positioning the product as a leading latestage pipeline candidate in Uveitis.

*
EYS606: Eyevensys

EYS606 is a novel nonviral gene therapy developed for chronic noninfectious uveitis (CNIU), combining plasmid DNA encoding a TNFneutralizing fusion protein with Eyevensys' proprietary electrotransfection system to achieve local, sustained intraocular expression of the therapeutic protein. Delivered by brief electrotransfer into the ciliary muscle, EYS606 aims to replace longterm systemic immunosuppression or repeated intravitreal injections and has demonstrated reduced intraocular inflammation and photoreceptor protection in preclinical uveitis models, with early clinical studies showing acceptable safety and signals of durable clinical response beyond six months after a single administration. EYS606 has received orphan designation in Europe for noninfectious uveitis and is being evaluated in Phase 1/2 and Phase 2 clinical trials, validating Eyevensys' EyeCET platform as a firstinclass ocular genedelivery approach within the Uveitis pipeline.

For more information on the Uveitis Emerging Drugs Profile, download DelveInsight's comprehensive Uveitis Pipeline Insight report [https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Uveitis Pipeline Report Provides

*
Detailed insights about companies developing therapies for Uveitis, including the aggregate number of therapies per company and the relative advancement of each program across clinical stages.

*
Different therapeutic candidates segmented into earlystage, midstage, and latestage of development for Uveitis treatment, covering Phase III, Phase II, Phase I, preclinical, discovery, and discontinued or inactive projects.

*
Uveitis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects, enabling a thorough understanding of competitive intensity and whitespace opportunities.

*
Uveitis drugs under development categorized by stage of development, route of administration, molecular target or pathway, monotherapy versus combination strategy, mechanism of action, and molecule type.

*
Detailed analysis of collaborations, licensing agreements, mergers and acquisitions, financing events, and regulatory designations that are shaping the clinical and commercial trajectory of emerging Uveitis therapies.

Learn more about Uveitis drugs opportunities in our comprehensive Uveitis research @ Uveitis Unmet Needs [https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Uveitis Companies

There are 15+ key companies developing therapies for Uveitis, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others focused on both anterior and posterior uveitis as well as uveitic complications.

According to DelveInsight's Uveitis pipeline and market analyses, this diversified mix of systemic and localdelivery players is expected to drive the introduction of biologics, gene therapies, and sustainedrelease formulations that can expand beyond traditional corticosteroidbased regimens.

DelveInsight's Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Discover the latest advancements in Uveitis treatment. Stay informed on how the Uveitis treatment is transforming @ Uveitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Scope of the Uveitis Pipeline Report

*
Coverage: Global

*
Uveitis companies: Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Tarsier Pharma, Oculis Pharma, Roche, Acelyrin, Priovant Therapeutics, ABIONYX Pharma, OKYO Pharma, and others driving innovation across local and systemic therapies.

*
Uveitis therapies: XIPERE, YUTIQ, ILUVIEN, TRS01, OCS02 (licaminlimab), RG6179, Baricitinib, Izokibep, EYS606, Brepocitinib, OCS01, Sirolimus (DE109), CER001, OK101, and additional emerging agents expected to reshape treatment algorithms in the coming years.

*
Uveitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination, allowing stakeholders to differentiate standalone diseasemodifying candidates from adjunctive or combinationbased strategies.

*
Uveitis Therapeutic Assessment by Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III, and discontinued or inactive candidates, supporting portfolio prioritization, licensing decisions, and competitive positioning across time horizons.

Table of Contents

*
Introduction

*
Executive Summary

*
Uveitis: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Uveitis - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Uveitis Key Companies

*
Uveitis Key Products

*
Uveitis Unmet Needs

*
Uveitis Market Drivers and Barriers

*
Uveitis Future Perspectives and Conclusion

*
Uveitis Analyst Views

*
Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uveitis-clinical-trial-pipeline-expands-as-15-companies-advance-15-targeted-ocular-inflammation-therapies-toward-market-entry-finds-delveinsight-santen-clearside-biomedical-tarsier-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.